A phase II study of S-1 in relapsed small cell lung cancer

S-1 is a new oral fluoropyrimidine derivative designed to enhance anticancer activity and reduce gastrointestinal toxicity. This phase II trial aimed to evaluate S-1 in patients with relapsed small cell lung cancer (SCLC). SCLC patients who had experienced treatment failure with ≥1 prior chemotherap...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: KUDO, KEITA, OHYANAGI, FUMIYOSI, HORIIKE, ATSUSHI, MIYAUCHI, EISAKU, TAHANAKA, HISASHI, YANAGITANI, NORIKO, SAITO, RYOUTA, KABURAKI, KYOUHEI, SAKATANI, TOSHIO, HORAI, TAKESHI, NISHIO, MAKOTO
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2013
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3915806/
https://ncbi.nlm.nih.gov/pubmed/24649158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2013.67
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky